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Early diagnosis and curative resection are the pre-
dominant factors associated with increased survival
in patients with gastric cancer. However, most gastric
cancer cases are still diagnosed at later stages. Since
most pathologic specimens are archived as FFPE sam-
ples, the ability to use them to generate expression
profiles can greatly improve cancer biomarker dis-
covery. We sought to uncover new biomarkers for
stomach preneoplastic metaplasias and neoplastic le-
sions by generating proteome profiles using FFPE
samples. We combined peptide isoelectric focusing
and liquid chromatography–tandem mass spectrom-
etry analysis to generate proteomic profiles from FFPE
samples of intestinal-type gastric cancer, metaplasia,
and normal mucosa. The expression patterns of se-
lected proteins were analyzed by immunostaining first
in single tissue sections from normal stomach, metapla-
sia, and gastric cancer and later in larger tissue array
cohorts. We detected 60 proteins up-regulated and 87
proteins down-regulated during the progression from
normal mucosa to metaplasia to gastric cancer. Two of
1560the up-regulated proteins, LTF and DMBT1, were vali-
dated as specific markers for spasmolytic polypeptide–
expressing metaplasia and intestinal metaplasia, re-
spectively. In cancers, significantly lower levels of
DMBT1 or LTF correlated with more advanced disease
and worse prognosis. Thus, proteomic profiling using
FFPE samples has led to the identification of two novel
markers for stomach metaplasias and gastric cancer
prognosis. (Am J Pathol 2012, 181:1560–1572; http://dx.doi.
org/10.1016/j.ajpath.2012.07.027)
Despite the general advances in endoscopic screening
and therapies, gastric cancer 5-year survival rates re-
main extremely poor,1 representing the second leading
cause of cancer-related death worldwide. The major
proximate cause of gastric cancer is chronic Helicobacter
pylori infection, which leads to a chronic inflammatory
response and subsequent oxyntic atrophy (loss of acid-
secreting parietal cells). In the fundus and corpus of the
atrophic stomach, two types of metaplasia have been
described: intestinal metaplasia (IM), characterized by
the presence of cells with intestinal and goblet cell mor-
phologic features, and spasmolytic polypeptide–ex-
pressing metaplasia (SPEM), which shows morphologic
characteristics of the deep antral glands and expresses
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polypeptide.2,3
Both types of metaplasia are associated with intestinal-
type gastric cancer4,5 and are considered neoplastic
precursors, although the mechanisms driving the pro-
gression from metaplasia to neoplasia remain unclear.
Recent studies in mice have found that SPEM originates
from the transdifferentiation of mature chief cells.6 Other
studies in Mongolian gerbils indicate that after H. pylori–
induced parietal cell loss, SPEM is the first metaplastic
lesion to evolve, whereas IM develops in the setting of
preexisting SPEM.7,8 Recent pathologic examinations in
humans have suggested that a similar relationship be-
tween SPEM and IM may exist in humans.9,10
Molecular profiling studies have identified a variety of
potentially useful markers for gastric cancer.11–14 How-
ever, owing to the high heterogeneity of gastric tumors,
no definitive markers have been established. High levels
of REG4 were detected in patients with gastric cancer
with metastasis, and its expression was correlated with
worse prognosis.14,15 Other studies have noted that
REG4 contributes to the resistance of gastric cancer to
fluorouracil-based chemotherapy; in addition, patients
with gastric cancer showed increased levels of serum
REG4. However, despite a specificity of 99%, the diag-
nostic sensitivity was only 36%.14,16 OLFM4 expression
has been associated with intestinal-type gastric cancer.
However, different proportions of OLFM4-positive tumors
were observed in two independent studies (65%17 in
contrast to 32%11), and its prognostic value is still not
clear.11,18 Inclusion of the less heterogenous metaplastic
lesions in the molecular profiling studies could allow a
better understanding of the molecular alterations during
gastric carcinogenesis and could lead to the develop-
ment of early-stage gastric cancer biomarkers. Indeed, in
a previous study, mRNA expression profiling of IM and
SPEM identified several metaplasia and gastric cancer
markers, including CDH17 and MUC13, as useful prog-
nostic markers for stage I gastric cancer.11 The com-
bined loss of four metaplasia markers (CDH17, REG4,
MUC13, and LGALS4) is an independent indicator of
survival in undifferentiated or stage II/III gastric cancer.19
Formalin-fixed, paraffin-embedded (FFPE) tissue sam-
ples are abundantly available in pathology archives, rep-
resenting a valuable resource for biomarker discovery.
Recent developments have facilitated the analysis of pro-
teomic profiles from paraffin-embedded tissues with
yields in the range of 90% of the peptides isolated from
frozen tissue, showing good equivalence between the
protein profiles from frozen and FFPE samples.20,21 This
innovation means that proteomic analysis can be per-
formed on paraffin-embedded tissue samples with de-
fined pathologic and histologic characteristics, allowing
more specific analyses in better-characterized samples.
In the present studies, we performed proteomic profil-
ing using macrodissected FFPE samples from intestinal-
type gastric cancer, stomach metaplasia, and normal
mucosa. These studies identified a variety of proteins that
are up-regulated in metaplasia and cancer. We identified
lactotransferrin (LTF) as a novel specific marker for SPEM
and deleted in malignant brain tumor 1 (DMBT1) as amarker for IM. In addition, we found that expression of
either LTF or DMBT1 influences the survival of patients
with gastric cancer.
Materials and Methods
Sample Description and Preparation
We selected 10 paraffin-embedded blocks from gastric
resections of intestinal-type tumors in the fundus where
both cancer and metaplasia areas were present. Based
on H&E staining of an adjacent section, the areas corre-
sponding to metaplasia (predominantly IM) or cancer
were macrodissected from 10-m sections to minimize
the stromal component. As a control group, normal fundic
mucosa with no sign of atrophic gastritis, IM, SPEM, or
gastric cancer was macrodissected from 10 blocks from
patients without gastric cancer. Detailed patient informa-
tion is shown in Supplemental Table S1 (available at
http://ajp.amjpathol.org). All the samples were obtained
from the Department of Surgery at Seoul National Univer-
sity Hospital (SNUH), Seoul, Korea, between July 1, 2007,
and July 1, 2008. This study protocol was approved by
the Institutional Review Board at SNUH, with written in-
formed consent provided by all the patients. Use of the
de-identified material was also approved by the Vander-
bilt University (Nashville, TN) Institutional Review Board.
Sample Preparation and Shotgun Proteomic
Analysis
Sample deparaffinization, digestion, and the subsequent
steps of isoelectric focusing of peptides and reverse-
phase liquid chromatography–tandem mass spectrome-
try (MS/MS) analysis were performed as previously de-
scribed with minor modifications.20 Macrodissected
slices were placed in separate centrifuge tubes. Paraffin
was removed with three washes in 1 mL of Sub-X clearing
medium (Surgipath, Richmond, IL), and rehydration was
achieved with three washes each in 1 mL of 100%, 85%,
and 70% ethanol. The samples were then digested with
trypsin (Promega Corp., Madison, WI) using a trifluoro-
ethanol (Acros, Geel, Belgium) digestion procedure de-
scribed by Wang et al22 with minor modifications. The
deparaffinized tissue was resuspended in 100 L of am-
monium bicarbonate (100 mmol/L, pH 8.0), heated to
80°C for 120 minutes, cooled on ice followed by the
addition of 100 L of trifluoroethanol, and sonicated twice
for 20 seconds followed by 30 seconds of incubation on
ice. The resulting homogenate was incubated at 60°C for
60 minutes, followed by the sonication steps as stated
previously herein. The protein concentration was deter-
mined using a bicichoninic acid assay (Thermo Scientific
Pierce, Rockford, IL). From the resulting homogenate, 50
g of protein was reduced with 10 mmol/L carboxyethyl-
phosphine (Thermo Scientific Pierce) and 25 mmol/L di-
thiothreitol (Acros) at 60°C for 30 minutes followed by
alkylation with 50 mmol/L iodoacetamide (Sigma-Aldrich,
St. Louis, MO) in the dark at room temperature for 20
minutes. The reduced and alkylated homogenate was di-
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pH 8.0 (Thermo Scientific Pierce), followed by the addition
of trypsin at 1:50 (w/w). The digest was incubated overnight
at 37°C, followed by freezing at 80°C and lyophilization.
Samples were resuspended in 1 mL of high-pressure liquid
chromatography water, desalted with Oasis HLB 96-well
Elution plates (30 m; Waters Corp., Milford, MA), and
evaporated in vacuo using a SpeedVac sample concentra-
tor (Thermo Fisher, Waltham, MA).
Isoelectric Focusing of Peptides
Isoelectric focusing of tryptic peptides was adapted from
the method of Cargile et al.23 Tryptic peptides (from 50
g of protein) were resuspended in 155 L of 6 mol/L
urea and were loaded in custom-ordered 7-cm (pH 3.5 to
4.5) ZOOM pH strips (Invitrogen, Carlsbad, CA) in a
ZOOM cassette and were allowed to rehydrate for 1 hour
at room temperature. The loaded strips were focused at
21°C on a ZOOM IPGRunner system (Invitrogen) using
the following program: step at 175 V for 15 minutes;
gradient to 2000 V over 45 minutes and held at 2000 V for
105 minutes. The strips were then cut into 10 (0.7-cm)
pieces and placed in separate wells of a 96-well enzyme-
linked immunosorbent assay plate. Peptides were eluted
from the strips as follows: 200 L of 0.1% formic acid for
15 minutes; 200 L of 50% acetonitrile/0.1% formic acid
for 15 minutes; 200 L of 100% acetonitrile/0.1% formic
acid for 15 minutes. Solutions of extracted peptides were
evaporated in vacuo, resuspended in 750 L of 0.1%
trifluoroacetic acid, desalted with Oasis HLB 96-well
Elution plates (30 m; Waters Corp.), and evaporated in
vacuo using a SpeedVac sample concentrator (Thermo
Fisher). Peptide solutions were resuspended in 25 L of
0.1% formic acid and were placed in sample vials for
liquid chromatography–MS/MS analysis.
Reverse-Phase Liquid Chromatography–MS/MS
Analysis
Liquid chromatography–MS/MS analyses were per-
formed on an LTQ Orbitrap hybrid mass spectrometer
(Thermo Fisher Scientific, San Jose, CA) equipped with a
nanoLC autosampler system (Eksigent, Dublin, CA). Pep-
tides were resolved on a fused silica capillary column
(100 m  11 cm; Polymicro Technologies, Phoenix, AZ)
packed with Jupiter 5 m 300 Å C18 (Phenomenex Inc.,
Torrance, CA) using an inline solid phase extraction col-
umn (100 mm  4 cm) packed with the same C18 resin
as that previously described.24 Liquid chromatography
was performed at room temperature at a flow rate of 0.6
L/min using a gradient mixture of 0.1% (v/v) formic acid in
water (solvent A) and 0.1% (v/v) formic acid in acetonitrile
(solvent B). A 95-minute gradient was performed with a
15-minute washing period diverted to waste after the pre-
column (100% solvent A for the first 10 minutes followed by
a gradient to 98% solvent A at 15 minutes) to allow for solid
phase extraction and removal of any residual salts. After the
initial washing period, a 60-minute gradient was performed
where the first 35 minutes was a slow, linear gradient from98% solvent A to 75% solvent A, followed by a faster gra-
dient to 10% solvent A at 65 minutes and an isocratic phase
at 10% solvent A to 75 minutes.
Centroided MS/MS scans were acquired using the
LTQ Orbitrap and an isolation width of 2m/z, an activation
time of 30 milliseconds, an activation q of 0.250, and
normalized collision energy of 30% using one microscan
with a maximum ion time of 100 milliseconds for each
MS/MS scan and one microscan with a maximum ion time
of 1000 milliseconds for each full MS scan. The mass
spectrometer was tuned before analysis using the syn-
thetic peptide TpepK (AVAGKAGAR) so that some pa-
rameters may have varied slightly from experiment to
experiment, but typically the tune parameters were as
follows: spray voltage of 2 kV, a capillary temperature of
150°C, a capillary voltage of 50 V, and a tube lens voltage
of 120 V. The automatic gain control target value was set
at 1,000,000 for the full MS and at 10,000 for the MS/MS
spectra. A full scan obtained for eluting peptides in the
range of 300 to 2000 atomic mass units was collected using
the Orbitrap portion of the instrument at a resolution of
60,000, followed by eight data-dependent MS/MS scans
(eighth most intense to most intense) using the LTQ portion
of the instrument with a minimum threshold of 500 set to
trigger the MS/MS spectra. MS/MS spectra were recorded
using dynamic exclusion of previously analyzed precursors
(0.6) for 60 seconds with a repeat of 1 and a repeat
duration of 1 and an exclusion list size of 50. Monoisotopic
precursor selection, nonpeptide monoisotopic recognition,
and charge state screening were enabled, with unassigned
and single charge states being rejected.
Database Searching and Statistical Analysis of
Spectral Counts
Proteins were identified using the MyriMatch algorithm,25
version 1.6.33, and the human IPI database, version 3.56,
as previously described.20 Spectral count data derived
from analysis using the IDPicker algorithm,26 version
2.6.165, were submitted to two statistical analyses. We
used a one-sided Jonckheere-Terpstra trend statistical
test 27 to assess the possibility of protein changes dem-
onstrating either an increasing or a decreasing trend from
normal to metaplasia to cancer. The tool for gene ontol-
ogy categorization in theWebGestalt toolkit (http://bioinfo.
vanderbilt.edu/webgestalt) was used to generate graphics
displaying the cell component categories of the proteins
differentially expressed in the stomach during the pro-
gression from normal mucosa to metaplasia to cancer. In
addition to the trend analysis, pairwise comparisons be-
tween cancer and normal, cancer and metaplasia, and
metaplasia and normal were performed using QuasiTel
software version 1.0 (Nashville, TN),28 which uses the
quasi-likelihood generalized linear modeling.
Immunostaining
Human stomach sections were deparaffinized and were
submitted to antigen retrieval in a pressure cooker using
the target retrieval solution (Dako North America Inc.,
y/SC1
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formed overnight at 4°C. For immunohistochemical anal-
ysis, secondary antibody incubation and diaminobenzi-
dine (DAB) development were performed using the Dako
EnVision system horseradish peroxidase DAB accord-
ing to the manufacturer’s instructions. In the case of im-
munofluorescence, appropriate secondary antibodies
conjugated with Alexa 488, Cy3, or Cy5 were used (1-
hour incubation at room temperature). Since the antibod-
ies against LTF, MIST1, and MPO were all made in rabbit,
for the co-labeling of LTF/MIST1 or MPO/LTF, we used
the TSA (tyramide signal amplification) plus fluorescein or
cyanine 3 kits (PerkinElmer, Waltham, MA) to detect the
first primary antibody of each pair (used in this case at a
dilution 10- to 20-fold higher than in regular staining).
After washes with 1X PBS and a second blocking step,
we performed the incubation with the second primary
antibody of each pair, which was then detected using
Alexa 448– or Cy3-conjugated secondary antibodies. In
both cases, we included a control slide for which the
second primary antibody of each pair was omitted. De-
tailed information on primary antibodies and their dilu-
tions are listed in Table 1.
RT-PCR and Real-Time PCR
For DMBT1 and LTF expression analysis throughout the
gastrointestinal tract, we used cDNA samples from the
human digestive system multiple tissue cDNA panel
(Clontech, Palo Alto, CA). PCR amplifications were per-
formed using the Advantage 2 PCR kit (Clontech), ac-
cording to the manufacturer’s instructions. The reaction
was allowed to denature for 4 minutes at 94°C, followed
by amplification (35 cycles): 45 seconds at 94°C, 1 min-
ute at 55°C, and 1 minute at 68°C. Amplification of TBP
(Tata-box binding protein) cDNA was performed as con-
trol for mRNA content. The following primers were used:
DMBT1_foward: 5=-GCTTTTCTGCCAGTGACCTTG-3=,
DMBT1_reverse: 5=-CTTGATGATGCCACCTGAGAC-3=;
LTF_foward: 5=-CCACAGTATGTCGCAGGCATT-3=, LTF_
reverse: 5=-CAGTGAATGGCTGAGGCTTTC-3=; and TBP_
foward: 5=-GAGCTGTGATGTGAAGTTTCC-3=, TBP_reverse:
Table 1. Antibodies Used for Immunostaining
Antibody name Company/c
Anti-TNXB Abnova (Taipei City, Tai
Anti-DDX5 Sigma-Aldrich/HPA0200
Anti-g340 (DMBT1) Abbiotec LLC (San Dieg
Anti-ESYT1 Sigma-Aldrich/HPA0168
Anti-LTF Novus Biologicals/NB30
Anti-NASP Abgent Inc. (San Diego,
Anti-NONO Sigma-Aldrich/AV40716
Anti-RCC1 Sigma-Aldrich/HPA0275
Anti-RUVBL2 Sigma-Aldrich/AV32379
Anti–pan-cytokeratin (PKC26) Abcam Inc. (Cambridge
Anti-cytokeratin Dako/Z0622
Anti-cytokeratin 8 (E432/GT3) Novus Biologicals (Little
Anti-MPO (myeloperoxidase) Dako/A0398
Anti-MIST1 Noncommercial36
Anti-MUC2 Santa Cruz Biotechnolog5=-TCTGGGTTTGATCATTCTGTAG-3=.For real-time PCR, total RNA was extracted from frozen
or RNAlater-preserved tissue samples using TRIzol (In-
vitrogen). Normal stomach samples were obtained from
Vanderbilt University Hospital from organ donors. Meta-
plasia samples from gastric resections were obtained at
Vanderbilt from the Cooperative Human Tissue Network
or from the Department of Surgery at SNUH. cDNA from
1.0 g of total RNA was prepared using a high-capac-
ity cDNA reverse transcription kit (Applied Biosystems,
Foster City, CA), according to the manufacturer’s in-
structions. Equal amounts of each cDNA were ana-
lyzed by real-time PCR with specific primers for
DMBT1, LTF, and TBP (same as described previously
herein) and by Express SYBR GreenER quantitative
PCR supermix (Invitrogen) in an ABI StepOne real-time
PCR system (Applied Biosystems). Each sample was
measured in triplicate.
Protein Expression Analysis on TMAs
The expression profiles of LTF and DMBT1 proteins were
analyzed using two TMAs. One is a metaplasia microar-
ray, previously described,29 created originally from tissue
samples from 33 Japanese patients. The cores that we
were able to analyze included areas of SPEM (n 12), IM
(n  9), foveolar hyperplasia (n  10), normal fundic
mucosa (n  9), normal antral mucosa (n  7), and
normal duodenum (n  2). The other TMA is a gastric
cancer microarray (SNUH-2004-GC) representing a col-
lection of 450 gastric adenocarcinomas resected at
SNUH in 2004. Detailed patient data for this cohort are
described elsewhere.11,30
For the metaplasia microarray, DMBT1 staining was
visualized by DAB development, whereas LTF was de-
tected by immunofluorescence in a double staining with
TFF2. For the gastric cancer microarray, both proteins
were detected by immunofluorescence. In both cases, an
antibody or an antibody mixture was included for keratin
detection. The TMAs were imaged using an Ariol SL-50
platform (Genetix, San Jose, CA) with a 20X objective.
The images from the metaplasia microarray were manu-
ally inspected and selected. For the gastric cancer array,
no. Concentration used
AB7268 1:4000
1:1000
/250390 1:200
1:500
1:500 (1:5000 for detection with TSA)
P2806b 1:500
1:200
1:200
1:500
b6401 1:500
1:200
)/NB110-56918 1:50
1:20,000 (detection with TSA kit)
1:1000
5334 1:200atalog
wan)/M
43
o, CA)
58
0-76
CA)/A
73
, MA)/a
ton, COthe percentage of epithelial cells (keratin staining) also
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mined using a pipeline constructed in the CellProfiler cell
image analysis software release 10997 (Cambridge,
MA).31 A representative graphical output depicting the
cells counted by the software is shown in Supplemental
Figure S1 (available at http://ajp.amjpathol.org).
Statistical Analysis
Mean protein level differences were analyzed by analysis
of variance; prognostic indicators included stage, Lauren
grade, metastasis, and histopathologic features. Pairwise
differences were examined for all statistically significant
prognostic indicators, and a Tukey adjustment for multi-
ple comparisons was applied. We used Cox proportional
hazards models to evaluate the difference in survival
experience among the staining quartiles for DMBT1 and
LTF; pairwise differences were tested using a Wald test
statistic.
Results
Proteomic Profiling of Stomach Metaplasia and
Gastric Cancer
We performed shotgun proteomic analysis on 10 macro-
dissected FFPE tissue samples collected from each of
three groups: i) normal fundic mucosa, ii) metaplasia in
the fundus, and iii) intestinal-type gastric adenocarci-
noma. Since control samples had a more limited amount
of tissue, we scaled down the isoelectric focusing prep-
aration from a typical 200-g input to analyze only 50 g
of protein.20,32 This analysis yielded approximately 2350
protein groups per sample (see Supplemental Table S2
at http://ajp.amjpathol.org). The overlap of proteins iden-
tified in the different tissue groups was 99%, although
the levels of proteins differed as assessed by spectral
counts, which correlate quantitatively with protein lev-
els.33–35 According to the Jonckheere Terpstra trend test
(P  0.01), 60 proteins were found to be up-regulated
and 87 proteins were found to be down-regulated across
the progression from normal mucosa to gastric cancer
(see Supplemental Tables S3 and S4 at http://ajp.
amjpathol.org). The cohort of up-regulated proteins was
predominantly represented by nuclear and membrane
proteins, whereas, in accordance with the parietal cell
loss observed during gastric metaplasia and cancer de-
velopment, mitochondrial proteins were overrepresented
in the group with decreased expression (see Supplemen-
tal Figure S2 at http://ajp.amjpathol.org). Box plots dis-
playing the levels of the top 20 statistically significant
up-regulated proteins from the trend analysis are
shown in Figure 1. Reflecting the progressive altera-
tions from normal mucosa to metaplasia and then to
cancer, in pairwise comparisons (see Supplemental
Tables S5 and S6 at http://ajp.amjpathol.org), we ob-
served (P  0.01 and fold change 1.5) 18 proteins up-
regulated in metaplasia and 46 up-regulated in cancer,
both compared with the normal mucosa. Nine of the pro-teins up-regulated in metaplasia were also among those
up-regulated in cancer.
We examined the expression patterns of nine (NASP,
DDX5, TNXB, NONO, RUVBL2, RCC1, LTF, DMBT1, and
ESYT) of the top 20 up-regulated proteins according to
the trend analysis in tissue sections from human normal
mucosa, metaplasia, and gastric cancer samples. The
first eight proteins were also in the cohort of those up-
regulated in cancer, as indicated by the pairwise analy-
sis. Two proteins, LTF and DMBT1, showed very specific
staining for metaplastic or neoplastic lesions and pre-
sented low expression levels or no detection in the nor-
mal mucosa (Figure 2). All the other proteins analyzed by
immunohistochemical analysis were detected in metapla-
sia and cancer but were also present in the normal mu-
cosa (see Supplemental Figure S3 at http://ajp.amjpathol.
org). LTF antibody labeled SPEM specifically but not IM
(Figure 2A). The presence of LTF protein in SPEM lesions
was confirmed using co-labeling with TFF2, whose ecto-
pic expression toward the base of the oxyntic mucosa is
a marker of SPEM (Figure 2B). In the normal mucosa, low
to moderate expression of LTF was detected in scattered
cells toward the bottom of the fundic glands. Those cells
represented a subpopulation of mature chief cells be-
cause they immunostained for the transcription factor
MIST1 (Figure 2C), a specific marker of mature chief
cells,36 and they did not express TFF2 (see Supplemental
Figure S4 at http://ajp.amjpathol.org). LTF is a component
of the secondary granules of neutrophils and, conse-
quently, in addition to the epithelial staining, strong label-
ing was observed in scattered infiltrating neutrophils
(confirmed by co-staining for myeloperoxidase) in the
normal mucosa (see Supplemental Figure S5 at http://
ajp.amjpathol.org).
DMBT1 was not detected in the normal mucosa but
showed strong expression in IM and cancer. The ab-
sence of DMBT1 expression in the normal stomach was
confirmed by RT-PCR using a panel of normal human
tissues from the gastrointestinal tract (Figure 2D). DMBT1
message was detected in all other regions of the gastro-
intestinal tract but not in the stomach. LTF message,
however, was detected throughout the entire gastrointes-
tinal tract, including the stomach (Figure 2D). In a previ-
ous mRNA profiling study, DMBT1 was found as one of
the top 10 up-regulated genes in IM; however, no signif-
icant increase in LTF message was detected.11 Using
quantitative real-time PCR, we confirmed a dramatic up-
regulation of DMBT1 message in stomach metaplasia
(Figure 2E). For LTF message levels, however, the differ-
ence between the normal and metaplasia groups was not
significant.
LTF and DMBT1 Are Early Markers for Different
Metaplastic Lineages
We extended the analysis of LTF and DMBT1 expression
to characterize their association with the metaplastic le-
sions. We used a small-scale tissue array (metaplasia
array) containing fundic mucosa sections displaying
SPEM and IM.29 DMBT1 and LTF were detected as spe-
s and m
h group
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Figure 3). In addition, we observed that both proteins
were expressed early in the metaplasia progression. A
small population of cells expressing DMBT1 was ob-
served in all the sections with SPEM (12 of 12) and in
most of the hyperplasia samples (9 of 10). These DMBT1-
positive cells were present luminal to regions with basally
located SPEM glands, in the upper third of the glands in
areas with no evident IM (Figure 3A). Also, LTF expres-
Figure 1. Top 20 proteins up-regulated in the stomach across the progressi
up-regulated using the Jonckheere-Terpstra trend test (P  0.01), we show b
counts) in each of the sample groups. The box plots show interquartile range
circle represents a individual sample value. The number of samples in eacsion was observed in all the hyperplasia samples, whichalready showed some evidence of SPEM development
based on the extension of TFF2 expression toward the
gland bottoms (Figure 3A). Strong LTF staining was ob-
served even in glands without TFF2-expressing cells
(Figure 3A), indicating that LTF expression may precede
up-regulation of TFF2 in SPEM. We also noted that sev-
eral of the glands with a few cells expressing DMBT1 (but
no evident IM) also contained cells with low levels of LTF,
usually in different cells (Figure 3, B and D). Co-staining
normal to metaplasia to cancer. For each of the top 20 proteins considered
representing the distribution of protein levels (normalized ratios of spectral
edians and whiskers indicate data value ranges excluding outliers. Each red
[normal, metaplasia (Meta), and cancer] was 10.on from
ox plotswith the two SPEM markers (LTF and TFF2) and DMBT1
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DMBT1 were TFF2 positive. We even observed rare cells
expressing all three of the markers (see Supplemental
Figure S6 at http://ajp.amjpathol.org). Also, in sections
stained for DMBT1, TFF2, and MUC2, in addition to the
cells expressing both TFF2 and DMBT1, we found cells
expressing TFF2 and low levels of the two IM markers
DMBT1 and MUC2 (Figure 4), suggesting that those hy-
brid glands represent a transitional stage between SPEM
and IM. Using a recently defined SPEM marker, Clus-
terin,37 in co-staining with DMBT1 and Ki-67, we ob-
served that although cells in the glands expressing only
Table 2. DMBT1 and LTF Protein Expression in the Metaplasia T
Protein Normal fundus Normal antrum
DMBT1 Not detected (0/9) Detected in 14% (1/7) Not de
LTF Scattered cells in Detected in 14% (1/7) Detect44% (4/9) (12/12)the SPEM marker were mostly negative for Ki-67, cells in
a transitional zone that express low levels of Clusterin and
DMBT1 are proliferative (Figure 5).
DMBT1 and LTF Expression in Gastric Cancers
We next sought to investigate the expression pattern of
LTF and DMBT1 proteins in a large number of gastric
cancer samples. We immunostained a tissue array set
(SNUH-2004-GC) containing 450 gastric cancer sam-
ples, most representing early-stage cases (45% at stage
I, 20% at stage II, 18% at stage III, and 17% at stage IV).
Figure 2. Expression of DMBT1 and LTF in
metaplasia and cancer. A: Immunohistochemical
analysis (DAB) using specific antibodies against
DMBT1 (right panels) and LTF (left panels) in
sections from normal stomach mucosa, stomach
with metaplastic lesions, and gastric adenocarci-
noma. Scale bars: 50 m. B: To confirm the LTF
staining in SPEM areas, we performed immuno-
fluorescence co-labeling using the antibody
against LTF (green; detected using an Alexa
488–conjugated secondary antibody) and an an-
tibody against TFF2 (red; detected using a Cy3-
conjugated secondary antibody). TFF2 staining
at the base of fundic mucosa glands is a marker
of SPEM. Scale bar  50 m. C: Immunofluores-
cence co-labeling of LTF (red; detected using the
TSA plus cyanine 3 kit) and MIST1 (green; de-
tected using an Alexa 488–conjugated second-
ary antibody) in normal fundic mucosa. D:
DMBT1 and LTF mRNA expression in the gas-
trointestinal tract. Specific primers for DMBT1 or
LTF messages were used for PCR amplifications
in a panel of cDNAs from tissues throughout the
gastrointestinal tract: esophagus (E), stomach
(S), duodenum (D), jejunum (J), ileum (I), ileo-
cecum (IC), cecum (C), ascending colon (Ca),
transverse colon (Ct), descending colon (Cd),
and rectum (R). Amplification of a TBP fragment
was used as loading control. m, molecular stan-
dard 100 bp DNA ladder, showing bands from
100-500 bp; nc, negative or non-template con-
trol. E:Quantitative real-time PCR of DMBT1 and
LTF in samples from normal stomach and stom-
ach with metaplastic lesions. Expression levels
are expressed as 2Ct, using TBP (endogenous
control) levels for normalization. Statistical anal-
ysis using a Mann-Whitney test indicated that
DMBT1 expression was significantly higher
(*P  0.05) in metaplasia than in normal mu-
cosa, whereas the difference for LTF levels be-
tween normal mucosa and metaplasia was not
significant (NS). Data are given as mean  SD.
rray
IM Hyperplasia
(0/12) Detected in 100% (9/9) Detected in 90% (9/10)
00% Not detected (0/9) Detected in 100% (10/10)issue A
SPEM
tected
ed in 1
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considered absent or very low expression), DMBT1 was
detected in 71.7% of the cancer samples, whereas LTF
was expressed in 44.1% of the cases. There was no
significant correlation of LTF or DMBT1 expression with
Lauren grade, World Health Organization grade, or the
presence of metastasis. Although the expression levels
(percentage of positive cells) of either DMBT1 or LTF
were similar between intestinal- and diffuse-type cancers
for both proteins, we observed two distinct staining pat-
terns that were basically associated with the different
histologic types. Representative staining for both proteins
in intestinal- and diffuse-type cancers is shown in Figure
6A. Overall, DMBT1 showed cytoplasmic punctate stain-
ing in 55.3% of the positive samples and a predominant
apical staining in 42.1% (2.6% of the positive samples did
not show a clear pattern). The cytoplasmic punctate pat-
tern was more frequently found in diffuse-type cancers
Figure 3. DMBT1 and LTF are early markers of different metaplastic lin-
eages. A TMA containing sections from normal stomach mucosa and cores
with foveolar hyperplasia, SPEM, or IM were immunostained using specific
antibodies against either DMBT1 (DAB) or LTF (green) with TFF2 (red).
Immunofluorescence primary antibody detection was performed as de-
scribed for Figure 2B. A: Area of foveolar hyperplasia with no morphologic
evidence of IM but with evidence of initial SPEM (expansion of TFF2 toward
the base). Note that although several glands at the base are not positive for
TFF2, most of them already show LTF expression. B: Higher magnification of
the area framed in A showing the presence of cells with low expression of
LTF and DMBT1 in the same gland. C: Section displaying areas of IM with
strong DMBT1 staining and areas of SPEM with strong LTF staining. D:
Higher magnification of the area framed in C. Scale bars: 50 m.(62.5% in diffuse type, 22.0% in intestinal type, and15.5% in mixed type), whereas the apical staining was
predominantly observed in intestinal-type cancers
(72.0% in intestinal type, 3.8% in diffuse type, and 24.2%
in mixed type). For LTF, the most common pattern
(67.0%) was a moderate-intensity cytoplasmic punctate
staining (Figure 6A). Diffuse-type cancers were predom-
inant in the group displaying this pattern (54.3% of diffuse
type, 26.1% of intestinal type, and 19.6% of mixed type).
The other pattern (33.0% of the positive samples) was a
very strong and diffuse cytoplasmic staining, which was
more frequently observed for intestinal-type tumors
(60.9% of intestinal type, 26.1% of diffuse type, and
13.0% of mixed type). According to the statistical analy-
sis, the only clinicopathologic factor that correlated with
DMBT1 or LTF expression was disease stage (Figure 6B).
For both proteins, the percentage of positive cells was
significantly higher in stage I cases. For survival analysis,
the expression levels of the proteins (percentage of pos-
itive cells) were divided into quartiles. For either DMBT1
or LTF, the lowest expression level correlated with signif-
Figure 4. Cells expressing the SPEM marker TFF2 and low levels of the
intestinal markers DMBT1 and MUC2 support the concept that SPEM pro-
gresses to IM. A tissue section from human stomach with areas of SPEM and
IM was immunostained using specific antibodies against DMBT1 (green;
detected with an Alexa 488–conjugated secondary antibody), TFF2 (red;
detected with a Cy3-conjugated secondary antibody), and MUC2 (pseudo-
colored to blue; detected with a Cy5-conjugated secondary antibody). DAPI
staining was pseudocolored to gray. The green arrow illustrates the cells
co-expressing TFF2 and DMBT1 (shown at higher magnification in the bot-
tom right panel). The pink arrow illustrates a transitional gland with cells
expressing the SPEM marker TFF2 and low levels of the intestinal markers
DMBT1 and MUC2 (shown at higher magnification in the bottom left
panel). Scale bars: 100 m (top panel); 25 m (bottom panel).
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any significant predictive benefit from the analysis of
combined LTF and DMBT1 expression.
As seen in the metaplasia array, we observed an in-
verse relationship for expression of DMBT1 and LTF in
metaplastic glands, with an overlap in units that seemed
to represent transitional glands in several metaplastic
areas associated with the tumors in the SNUH-2004-GC
tissue array (Figure 7A). Cells expressing DMBT1 and
cells expressing LTF were observed in single glands, but
they were usually in different domains, although in some
cases we detected a very low expression level of LTF in
cells expressing DMBT1.
Discussion
Since FFPE specimens compose most archived patho-
logic samples, recent advances in using paraffin-embed-
ded tissues for proteomic profiling20 have great potential
to increase biomarker discovery. We used this approach
herein for stomach tissues, generating consistent pro-
teome profiles from normal mucosa, stomach metaplasia,
and cancer using FFPE samples. The present data sup-
port the use of this method even when smaller amounts of
total protein are available (50 g instead of the 200 g
Figure 5. Cells expressing the SPEM marker Clusterin and the IM marker
DMBT1 are proliferative, in contrast to cells expressing the SPEM marker
only. A tissue section from human fundic stomach displaying areas of SPEM
and IM was immunostained using specific antibodies against Clusterin
(green; detected with an Alexa 488–conjugated secondary antibody), Ki-67
(red; detected with a Cy3-conjugated secondary antibody), and DMBT1
(pseudocolored to blue; detected with a Cy5-conjugated secondary anti-
body). Higher magnifications of the areas depicted in the white squares in
the top panel are shown in the bottom panels. Scale bars: 100 m (top
panels); 25 m (bottom panels).used in the previous report20). Loss of parietal cells in-duced by H. pylori infection is a prerequisite event in the
development of metaplastic and neoplastic lesions in the
stomach fundic mucosa. The fact that mitochondrial pro-
teins (especially abundant in parietal cells) were the ma-
jor class of down-regulated proteins in metaplasia and
cancer indicates that the profiles we generated reflect the
biological changes characteristic of the atrophic, meta-
plastic, and neoplastic stomach mucosa. Further sup-
porting this conclusion, there were a higher number of
up-regulated proteins in cancer than in metaplasia com-
pared with normal.
IM is a well-established preneoplastic lesion for intes-
tinal-type gastric cancer,38,39 and SPEM has gained in-
Figure 6. DMBT1 and LTF expression in gastric cancer. DMBT1 and LTF
expression (green; detected with an Alexa 488–conjugated secondary anti-
body) was evaluated in a TMA containing 450 gastric cancer samples. In both
cases, the TMA was co-stained with an anti–pan-cytokeratin antibody (red;
detected with a Cy3-conjugated secondary antibody) as a marker for epithe-
lial cells. A: Representative pictures of DMBT1 and LTF staining in intestinal
and diffuse types of gastric cancer. The LTF/keratin staining, (bottom left
panel) shows the single channel image of keratin staining, included to show
that the cells (indicated by the arrows) displaying strong LTF staining were
keratin positive. Scale bar  50 m. B: DMBT1 and LTF expression inversely
correlates with tumor stage. The percentage of DMBT1- and LTF-positive
cells is significantly lower in stages II, III, and IV than in stage I. Data are
given as mean SD. C: Survival impact of DMBT1 or LTF expression. Protein
expression levels in patients, represented by percentage of positive cells,
were divided into patient quartiles that were used to construct the survival
curves. The log-rank test P value for DMBT1 was 0.0076 and for LTF was
0.0072. For pairwise analysis, the statistical models applied showed statisti-
cally significant differences between the first and second and first and third
quartiles for DMBT1 (P 0.015 and 0.002, respectively) and between the first
and third and first and fourth quartiles for LTF (P  0.012 and 0.003,
respectively); all other pairwise differences were nonsignificant at the 0.05
level of significance. Overall, patients with the lowest expression of either
LTF or DMBT1 (quartile 1) showed poorer survival.
n differe
BT1 an
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though some important SPEM markers have been
identified, including HE4/WFDC241 and Clusterin,37 the
repertory of biomarkers for SPEM diagnosis is still limited.
We identified LTF as a new SPEM marker that may con-
tribute to the early precise detection of SPEM in human
stomach. LTF differs from other SPEM markers, including
TFF2, HE4, and Clusterin, because it is expressed in a
subpopulation of chief cells in the normal mucosa. This
finding supports the concept that SPEM in humans de-
rives, at least in part, from mature chief cells, as has been
demonstrated in the mouse.6 The presence of IM in the
stomach is usually evident even in routine H&E-stained
sections. Nevertheless, since DMBT1 expression seems
to precede the appearance of the characteristic IM mor-
phologic features, its expression analysis may help the
diagnosis of transitions toward IM at an early stage.
Sugano and colleagues42 recently demonstrated that
metaplasia markers (some intestinal markers and TFF2)
could be detected very early during metaplasia develop-
ment, preceding the morphologic changes characteristic
of each lesion. In addition to the potential use of DMBT1
and LTF as early metaplasia markers, their expression
pattern in gastric cancer makes them new candidate
markers for predicting patient outcome.
LTF (lactoferrin or lactotransferrin) is an 80-kDa iron-
Figure 7. DMBT1 and LTF show an opposite expression gradient in the stom
adjacent to a gastric adenocarcinoma showing DMBT1 and LTF expression i
LTF and DMBT1 were detected in green and keratin in red. B: Model of DMbinding glycoprotein expressed mainly in glandular epi-thelial cells and in the developing neutrophils, where it is
stored in the secondary granules.43,44 The biological
functions of LTF go far beyond just iron homeostasis and
include host defense, anti-inflammatory activity, cell
growth and differentiation, and cancer development. LTF
can activate gene expression via induction of intracellular
signaling pathways, including NF-B.45 Although a re-
cent study showed that LTF is responsible for the loss or
reduction of ER-, PR, and HER-2 in triple-negative
breast cancer and contributes to increased invasive be-
havior of breast cancer cells,46 most studies have char-
acterized an LTF role in cancer as antitumorigenic.44 The
present data, showing that most cancers demonstrate
low expression levels of LTF and that the lowest expres-
sion levels correlate with the poorest outcome, support
the concept of a protective role of LTF against gastric
cancer.
DMBT1 is a 340-kDa protein with 14 repeats of the
scavenger receptor cysteine-rich domain, two C1r/C1s
Uegf Bmp1 domains, and a carboxy-terminal zona pel-
lucida domain. Other names for the DMBT1 gene prod-
ucts include salivary agglutinin, gp-340, CRP-ductin
(mouse), muclin (mouse), and hensin (rabbit). It is a com-
plex molecule that has been implicated mainly in innate
immune defense and epithelial cell differentiation.47,48
Hensin, the rabbit orthologue of DMBT1, is responsible
ing progression of metaplasia. A: Representative images of a metaplastic area
nt regions of the same gland displaying an opposite gradient of expression.
d LTF expression during stomach metaplasia and neoplastic progression.ach durfor the conversion of - to -intercalated cells in the
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example of transdifferentiation. DMBT1 is predominantly
expressed in epithelial cells, and in humans, the highest
levels of DMBT1 expression were observed in trachea,
lungs, and the gastrointestinal tract. Previous studies re-
ported the presence of DMBT1 message or protein in
normal human stomach.51,52 In the present study, we
confirmed abundant expression of DMBT1 message
throughout the gastrointestinal tract but not in the normal
stomach corpus. The use of whole stomach samples
containing the antral region in those previous studies
could explain this difference in results since we did ob-
serve DMBT1 protein expression in the antrum, in a sub-
population of cells in the isthmus/neck region. Down-
regulation of DMBT1 expression has been described in
breast,53 lung,54 esophageal,48 and skin55 cancers. Pre-
vious studies, however, have shown increased DMBT1
expression in gastric cancer.51,56 Using a large-scale
sample cohort, we confirmed DMBT1 up-regulation in
gastric tumors compared with in normal stomach, and, in
addition, we showed that the lowest expression level of
DMBT1 was associated with poor patient survival.
Note that the proteins we detected as early markers for
SPEM and IM (LTF and DMBT1, respectively) are both
connected to the inflammatory response and cell differ-
entiation. Inflammation is a key factor for metaplasia-
neoplasia progression in the stomach. Studies in mouse
models have revealed that although loss of parietal cells
alone is sufficient to induce the appearance of SPEM, the
progression to a more proliferative metaplasia and sub-
sequent dysplasia requires the presence of inflamma-
tion.40,57 Expression of LTF and DMBT1 as an initial re-
sponse to infection and inflammation may lead to the
induction of altered differentiation pathways in the cells of
the gastric mucosa, contributing to the establishment of
metaplastic lesions.
The expression pattern of LTF and of other SPEM
markers and DMBT1 also supports the concept that hu-
man SPEM evolves into IM. Cells expressing both the
SPEM marker Clusterin and DMBT1 are proliferative, in
contrast to cells expressing Clusterin only. Those cells
possibly represent the precursors of the IM lesions that
are marked by high levels of DMBT1 expression and
increased proliferation. Studies in animal models indicate
that after parietal cell loss, SPEM is the first metaplastic
lesion to evolve, whereas IM will develop from SPEM.7,8 A
recent study by Varon et al58 demonstrated that SPEM
associated with long-term Helicobacter felis infection (1
year) is associated with the emergence of intestinal mark-
ers. Thus, mouse SPEM cells in a more advanced meta-
plastic stage acquire a more intestinal-like expression
profile. We recently found similar intestinalizing tran-
scripts in SPEM lineages from 12-month H. felis–infected
mice, including DMBT1.37 In humans, the metaplasia-
neoplasia cascade (Figure 7B) would be marked by early
expression (or up-regulation) of LTF in SPEM (and pos-
sible pre-SPEM cells) that decreases when the cells
progress to IM and start to express DMBT1. Consistent
with previous studies showing that loss of metaplasia
markers correlates with worse prognosis in patients with
gastric cancer,11,19 we showed herein that during cancerprogression, the levels of both proteins decrease, and
this has a negative effect on patient survival.
In summary, we demonstrated the utility of proteomic
profiling of FFPE gastric tissues as an effective approach
to identify relevant biomarkers. These investigations iden-
tified LTF and DMBT1 as strong markers of SPEM and IM,
respectively. The patterns of LTF and DMBT1 expression
support the concept that SPEM gives rise to IM. In addi-
tion, we showed that loss of LTF or DMBT1 expression in
gastric tumors correlates with a poor prognosis.
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